Sharp Mesa Vista Clinical Research Center
Sharp Mesa Vista Alzheimer's Clinical Trials
Sharp Mesa Vista Hospital is enrolling both men and women ages 50 to 90 for studies of investigational medicines for Alzheimer's disease and mild cognitive impairment. To qualify, you must:
- Attend study visits at Sharp Mesa Vista Hospital's Clinical Research Center
- Have a caregiver (spouse, relative or health care aide) who can accompany you to study visits and help monitor your study progress
About these studies.
This study is for individuals with early Alzheimer's disease or mild cognitive impairment. The study will last for approximately two years and participants will receive either the study drug (Elenbecestat) or a placebo. The study is investigating the safety and effectiveness of Elenbecestat on symptoms of Alzheimer's disease.
This study is for people who have been diagnosed with mild Alzheimer's disease and are not currently taking any medications for Alzheimer's. The study will last for six months and participants will receive either an investigational drug (TRx0237) or a placebo. The study will assess the safety and effectiveness of TRx0237 and determine if the investigational drug will slow the disease progression
This study is for people who have experienced gradual memory changes for at least six months. The study will last for approximately two and a half years and participants will receive the study drug (LY3002813) or a placebo. The study will evaluate the safety and effectiveness of the investigational drug and will determine if it will have any effect in reducing the amount of beta amyloid plaques.
How to enroll.
Participation is confidential and trials are safely conducted under the supervision of experienced physicians and research specialists. Eligible participants may be compensated for time and travel. Transportation to and from study visits can be provided upon request.